Filing Flows › Biotricity (BTCY) › Q4 FY26
Biotricity (BTCY) Q4 FY26 earnings results (fourth quarter fiscal 2026)
10-K filed Jul 14, 2026
Biotricity (BTCY) reported revenue of $4.3M for the fourth quarter fiscal 2026 (Q4 FY26), +15% from a year earlier and +7% from the quarter before. Operating margin was 16.3%, net loss $324K (7.6% of revenue).
Biotricity, Q4 FY26: revenue $4.3M (+15% year over year), operating margin 16.3%, net loss $324K, operating cash flow −$21K. The chart follows the revenue to costs, profit and cash.
| Q4 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $4.3M | +7% | +15% |
| Operating profit | $695K | +58% | — |
| Net earnings | −$324K | — | — |
| Operating cash flow | −$21K | — | — |
What changed
Revenue was $4.3M in Q4 FY26, up 15% year over year and up 7% from the previous quarter. Technology Fees was the largest line at 92% of revenue.
Gross margin was 80.0%, down 0.5 points from Q4 FY25. Operating profit was $695K, a 16.3% margin (up 39.4 points year over year). Operating expenses fell 29% while revenue rose 15%. The fastest-growing cost line was Research & development (+47%). The quarter ended with a net loss of $324K, narrower than the previous quarter's $717K loss. Net interest and other expense of $1.0M was the main reason.
Operating cash flow was −$21K. Non-cash charges added back $1K of depreciation and $8K of share-based compensation. Working capital and other items added $294K.
Questions
What was Biotricity's revenue in the fourth quarter fiscal 2026?
Biotricity (BTCY) reported revenue of $4.3M for the fourth quarter fiscal 2026 (Q4 FY26), +15% from a year earlier and +7% from the quarter before.
Was Biotricity profitable in the fourth quarter fiscal 2026?
Operating profit was $695K (16.3% of revenue) and net loss $324K.
Source: Biotricity 10-K on SEC EDGAR.